FDAnews Device Daily Bulletin

ABBOTT LABS STILL HAS 'CONSIDERABLE' UPSIDE POTENTIAL

Nov. 30, 2005
A A

Banc of America Securities reiterated a "buy" rating on Abbott Laboratories and lowered the target price to $46 from $49. The research firm said "there is still much to like" about Abbott, and that shares of the healthcare-products company have "considerable" upside potential.

Forbes (http://www.forbes.com/2005/11/28/abbott-labs-earnings-1128markets14_print.html)